50 related articles for article (PubMed ID: 19277661)
1. Integrated drug response prediction models pinpoint repurposed drugs with effectiveness against rhabdomyosarcoma.
Baek B; Jang E; Park S; Park SH; Williams DR; Jung DW; Lee H
PLoS One; 2024; 19(1):e0295629. PubMed ID: 38277404
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and Evaluation of Antiproliferative Activity, Topoisomerase IIα Inhibition, DNA Binding and Non-Clinical Toxicity of New Acridine-Thiosemicarbazone Derivatives.
Sousa G; de Almeida MCF; Lócio LL; Dos Santos VL; Bezerra DP; Silva VR; de Almeida SMV; Simon A; Honório TDS; Cabral LM; Castro RN; de Moura RO; Kümmerle AE
Pharmaceuticals (Basel); 2022 Sep; 15(9):. PubMed ID: 36145320
[TBL] [Abstract][Full Text] [Related]
3. Strongylopus grayii tadpole blastema extract exerts cytotoxic effects on embryonal rhabdomyosarcoma cells.
Harrison V; Khan SF; Damerell V; Bleloch J; ArulJothi KN; Sinkala M; Lennard K; Mulder N; Calder B; Blackburn J; Prince S
In Vitro Cell Dev Biol Anim; 2022 Sep; 58(8):679-692. PubMed ID: 35947290
[TBL] [Abstract][Full Text] [Related]
4. Sequestration of AS-DACA into acidic compartments of the membrane trafficking system as a mechanism of drug resistance in rhabdomyosarcoma.
Williams M; Catchpoole D
Int J Mol Sci; 2013 Jun; 14(7):13042-62. PubMed ID: 23799359
[TBL] [Abstract][Full Text] [Related]
5. Intracellular trafficking as a determinant of AS-DACA cytotoxicity in rhabdomyosarcoma cells.
Wolf SJ; Huynh T; Bryce NS; Hambley TW; Wakelin LP; Stewart BW; Catchpoole DR
BMC Cell Biol; 2011 Aug; 12():36. PubMed ID: 21861933
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of topoisomerases as anticancer drugs: problems and prospects.
Dwarakanath BS; Khaitan D; Mathur R
Indian J Exp Biol; 2004 Jul; 42(7):649-59. PubMed ID: 15339028
[TBL] [Abstract][Full Text] [Related]
7. DNA topoisomerases in cancer chemotherapy: using enzymes to generate selective DNA damage.
Nitiss JL
Curr Opin Investig Drugs; 2002 Oct; 3(10):1512-6. PubMed ID: 12431029
[TBL] [Abstract][Full Text] [Related]
8. Structure-activity relationships for substituted bis(acridine-4-carboxamides): a new class of anticancer agents.
Gamage SA; Spicer JA; Atwell GJ; Finlay GJ; Baguley BC; Denny WA
J Med Chem; 1999 Jul; 42(13):2383-93. PubMed ID: 10395479
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the action of the topoisomerase II poison amsacrine by simple aniline derivatives: evidence for drug-protein interactions.
Finlay GJ; Atwell GJ; Baguley BC
Oncol Res; 1999; 11(6):249-54. PubMed ID: 10691026
[TBL] [Abstract][Full Text] [Related]
10. Topoisomerase I/II selectivity among derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA).
Bridewell DJ; Finlay GJ; Baguley BC
Anticancer Drug Des; 2001 Dec; 16(6):317-24. PubMed ID: 12375884
[TBL] [Abstract][Full Text] [Related]
11. 5,7-Disubstituted analogues of the mixed topoisomerase I/II poison N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA): DNA binding and patterns of cytotoxicity.
Spicer JA; Finlay GJ; Baguley BC; Velea L; Graves DE; Denny WA
Anticancer Drug Des; 1999 Feb; 14(1):37-45. PubMed ID: 10363026
[TBL] [Abstract][Full Text] [Related]
12. Comparative biodistribution and metabolism of carbon-11-labeled N-[2-(dimethylamino)ethyl]acridine-4-carboxamide and DNA-intercalating analogues.
Osman S; Rowlinson-Busza G; Luthra SK; Aboagye EO; Brown GD; Brady F; Myers R; Gamage SA; Denny WA; Baguley BC; Price PM
Cancer Res; 2001 Apr; 61(7):2935-44. PubMed ID: 11306471
[TBL] [Abstract][Full Text] [Related]
13. In vitro assessment of novel transcription inhibitors and topoisomerase poisons in rhabdomyosarcoma cell lines.
Wolf SJ; Wakelin LP; He Z; Stewart BW; Catchpoole DR
Cancer Chemother Pharmacol; 2009 Nov; 64(6):1059-69. PubMed ID: 19277661
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
